The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.
The 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer took place in San Diego, California, from March 16 to 18, 2024, where experts in the field of gynecologic oncology met to learn and share results of the latest research.
The latest findings across ovarian, cervical, and endometrial cancers took center stage, including compelling data from the phase 3 KEYNOTE-868 trial (NCT03914612) investigating pembrolizumab (Keytruda) plus chemotherapy in endometrial cancer.
One of the most exciting presentations came from the phase 3 RUBY trial (NCT03981796), where “unprecedented” survival for patients with endometrial cancer was observed with the combination of dostarlimab-gxly (Jemperli) plus chemotherapy.
Treatment of perivascular epithelioid sarcoma (PEComa) with nab-Sirolimus (Fyarro; ABI-009) also was anticipated as the topic of multiple presentations at the meeting.
Social determinants of health—poverty, race, ethnicity, and treatment access—play a critical role in occurrence rates cervical cancer across the United States.
The combination of pembrolizumab plus chemotherapy conferred a positive overall survival (OS) outcome for patients with endometrial cancer, according to findings from the phase 3 NRG-GY018/KEYNOTE-868 trial.
Dostarlimab and carboplatin/paclitaxel chemotherapy delivered a 31% improvement in OS vs placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer, regardless of microsatellite instability (MSI) status, according to findings from a second interim analysis of part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Olaparib (Lynparza) plus cediranib did not appear to deliver a statistically significant improvement in progression-free survival (PFS) and OS vs standard-of-care chemotherapy among patients with platinum-resistant or -refractory epithelial ovarian cancer.
Patient-reported outcomes (PROs) from the phase 3 MIRASOL trial (NCT04209855) showed that patients with folate receptor-alpha positive, platinum-resistant ovarian cancer treated with mirvetuximab soravtansine (Elahere) had a better health-related quality of life compared with the investigator’s choice of chemotherapy.
In locally advanced cervical cancer, the combination of neoadjuvant tislelizumab (Tevimbra) plus chemotherapy was shown to be safe with encouraging antitumor activity based on a pathologic complete response in 60.9% and an optimal pathologic response in 73.9% of patients.
A phase 2 study (NCT05997017) investigating the combination of nab-Sirolimus plus letrozole (Femara) in patients with advanced or recurrent endometrial cancer began enrollment in December 2023.
Nab-Sirolimus delivered rapid and durable responses in patients with PEComa, according to a subgroup analysis of the phase 2 AMPECT study (NCT02494570).
Disparities in clinical characteristics and outcomes were noted between Black and White women with endometrioid endometrial cancer, particularly with Black patients experiencing an increased risk of death, according to findings from a retrospective study of patients in real-world registries and GOG/NRG randomized phase 3 trials.
Using ChatGPT as a tool to pose genetic counseling questions delivered accurate responses for patients with gynecologic cancers.
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More